Corbus Pharmaceuticals presents pre-clinical characterization of CRB-701

Corbus Pharmaceuticals announced that a poster characterizing the pre-clinical validation of CRB-701, a next generation antibody drug conjugate targeting nectin-4 was presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in Boston on October 14th 2023. The poster, titled Development of CRB-701: A novel site-specific Nectin-4 targeting ADC, provides an overview of the pre-clinical development and validation of the differentiating features of CRB-701, including: Site specific conjugation chemistry and a stable linker that leads to low payload release in plasma. A novel nectin-4 targeting monoclonal antibody with improved speed of internalization and a pharmacokinetic profile that can support Q3W dosing in the clinic. A safety profile supports dosing at higher ADC exposures relative to enfortumab vedotin. CRB-701 demonstrates statistically significant tumor growth inhibition in preclinical models that express mid- and high-levels of nectin-4, similar to EV. However, in a low expression model, CRB-701 also exhibited statistically significant tumor growth inhibition in a primary bladder tumor model with low nectin-4 expression where EV did not. CRB-701 has a longer half-life than EV and is being dosed on a Q3W schedule in the clinic. When dosed at 1.2 mg/kg CRB-701 demonstrated notably lower levels of free MMAE.